GlaxoSmithKline

  • Can This HIV Drug Challenge Gilead’s Domination?

    By Kanak Kanti - August 19, 2013 | Tickers: GILD, GSK, PFE

    ViiV Healthcare, a joint venture by Pfizer (NYSE: PFE) and GlaxoSmithKline (NYSE: GSK) formed in 2009 with both companies transferring their HIV assets to the new company, got FDA approval for its first new HIV product, Tivicay. Its original developer is Japan’s Shionogi Pharma, which the group joined last year.

    The drug has the potential of raising the groups’ fortunes to the tune of $5 billion provided it is more »

  • Could This DMD Treatment Become a Blockbuster Drug?

    By Leo Sun - August 17, 2013 | Tickers: GSK, RNA, PTCT, SRPT

    Duchenne muscular dystrophy (DMD) is a muscle-wasting disease caused by a genetic mutation in the dystrophin gene, the largest gene on the X chromosome, which affects one in every 2,400 male births. Muscle weakness in DMD patients generally spreads from the legs to the pelvis, eventually reaching the arms, neck and other areas, confining most patients to a wheelchair by age 12 and resulting in a maximum lifespan of more »

  • Is This Healthcare Stock Underrated?

    By Leo Sun - August 16, 2013 | Tickers: ELN, GSK, JNJ, PRGO, TEVA

    Shares of Perrigo Company (NYSE: PRGO), one of the world’s largest healthcare suppliers, slid with the broader market on August 15, after the company reported fourth quarter earnings that topped analyst estimates but missed revenue forecasts. Over the past month, Perrigo has drawn a lot of criticism for its $8.6 billion takeover of Irish pharmaceutical Elan Corporation (NYSE: ELN), which redcued its corporate tax rate by moving its more »

  • Which of These Biotechs Can Beat the Bird Flu?

    By Leo Sun - August 15, 2013 | Tickers: BOTA, GILD, GSK, RHHBY, SNY

    The H7N9 bird flu epidemic, which recently claimed its 44th victim in China, has had a widespread impact across the markets, ravaging the airline, hospitality and restaurant sectors in particular. Since the end of March, the Chinese government reported 134 new cases of N7N9, with a single overseas case reported in Taiwan.

    H7N9 is more lethal than its predecessor, H5N1, which claimed more than 360 lives over the past decade more »

  • Healthier Days Loom as 3 Big Pharmas Move on Dengue Shots

    By Arturo Cuevas - August 12, 2013 | Tickers: GSK, MRK, SNY

    Mosquito bites sure suck, literally and figuratively. But more so if these are delivered by the insects’ female species, which cause viral infections. But forget malaria. It is dengue fever, also known as hemorrhagic fever, which now ranks as the world’s most virulent mosquito-borne viral disease, says the World Health Organization. Some 3 billion people in 100 countries, or roughly half of mankind, are estimated to be at risk more »

  • This Company's Debt Might Be a Concern

    By Harriet Tramer - August 9, 2013 | Tickers: AZN, GSK, NVS

    GlaxoSmithKline (NYSE: GSK) has been accused of making illegal payments to Chinese doctors and government officials by siphoning them through travel agencies. If these allegations are substantiated -- Glaxo officials at the highest levels have acknowledged that company executives might have broken the law -- they could have serious ramifications for the firm’s future. By some accounts, however, these entanglements are simply the price of doing business, something that companies move more »

  • This Company Is Tackling Multiple Sclerosis Head On

    By Kanak Kanti - August 7, 2013 | Tickers: BIIB, GSK, SNY

    Note: This article has been amended to better reflect Lemtrada's market position.

    Currently existing immunomodulatory drugs that treat Multiple Sclerosis only work to treat relapse or attacks, manage symptoms, or modify the course of the disease. MS has no cure. These drugs have too many side effects due to their lack of target specificity. Another class of drugs, recently being developed, are protein based therapies (monoclonal antibodies or mAbs more »

  • GlaxoSmithKline: Victim or Villain in China?

    By Victor Alagbe - August 7, 2013 | Tickers: AZN, GSK, JNJ, SNY

    The last reported record of something British forcing drugs on the Chinese people was during the opium wars of which we should let sleeping dogs lie. However, it appears that GlaxoSmithKline (NYSE: GSK), a British company has been caught in the act forcing drugs on the Chinese people albeit through prescriptions. The story of GSK's bribery scandal in China is no longer news; but I would like to point more »

  • Potential Paradigm Shifting Technology from a Small Biotech

    By Kanak Kanti - August 2, 2013 | Tickers: GSK, RNA, SRPT

    Two biotech companies, Sarepta Therapeutics (NASDAQ: SRPT) and Prosensa Holdings (NASDAQ: RNA) are involved in a race to be the first to get their candidate approved for treatment of DMD, a rare recessive form of muscular dystrophy. However, what is involved is a lot more than just the financial angle. Approvals of these two drugs can potentially change the focus of future research in discovery of new drugs.

    The race more »

  • This Cancer Biotech Is Looking for Other Green Pastures

    By Kanak Kanti - August 1, 2013 | Tickers: ARRY, AZN, GSK

    Array Biopharma  (NASDAQ: ARRY), a biotech company primarily focused on discovery of drugs for cancer treatment, is making forays into the asthma market. The company recently announced encouraging results – 6.8% improvement in FEV1 versus placebo – of Phase II clinical trials of ARRY-502, an oral medication for management and treatment of asthma. FEV1 (forced expiratory volume in one second) is a measure of lung function and one of the parameters more »

  • Which of These COPD Treatments Will Come Out on Top?

    By Leo Sun - July 30, 2013 | Tickers: GSK, NVS, THRX

    To most people, cigarettes are often associated with lung cancer. However, smoking also causes other severe respiratory problems, such as COPD (chronic obstructive pulmonary disease). COPD occurs as a result of emphysema, which breaks down lung tissues -- causing chronic cough, increased sputum production, and shortness of breath. COPD is currently the third leading cause of death in the United States, and is estimated to cost the country $42.6 billion more »

  • 3 Reasons GlaxoSmithKline Will Survive the China Scandal

    By Anjum Khan - July 29, 2013 | Tickers: GSK, JNJ, MRK

    GlaxoSmithKline (NYSE: GSK) has been accused of the violation of Chinese laws wherein the company’s key officials have used around 700 agencies and firms for increasing the sales and prices of drugs by bribing hospitals and doctors in China. The company has transferred around $489 million to these agencies. Four of the company’s executives are detained. This includes the vice president, the legal affairs director, the business development more »

  • Big Pharma’s Bribery Blues

    By Leo Sun - July 24, 2013 | Tickers: AZN, LLY, GSK, PFE

    Big pharmaceutical companies have a knack for getting into trouble with governments. Over the past four years, major names in big pharma - including Pfizer (NYSE: PFE), Novartis and GlaxoSmithKline (NYSE: GSK) - have been fined billions of dollars in the United States for giving physicians kickbacks and perks to promote off-label marketing.

    This month, charges of bribery have surfaced in China. The Chinese government is currently investigating GlaxoSmithKline for allegedly running more »

  • A One of a Kind Flagship Drug for Your Irritable Bowel

    By Kanak Kanti - July 24, 2013 | Tickers: GSK, IRWD, SCMP

    Ironwood Pharmaceuticals (NASDAQ: IRWD) develops drugs for the treatment of gastrointestinal diseases.

    The company recently launched its flagship product Linzess in the U.S to treat irritable bowel syndrome (IBS). The product was developed and commercialized in collaboration with Forest Laboratories for North America. The same product is under various development stages to promote in different geographies including Europe and Asia.

    IBS market

    IBS is a gastrointestinal disorder caused due more »

  • 3 Healthcare Stocks for Growth and Dividends

    By Ishtiaq Ahmed - July 23, 2013 | Tickers: AZN, GSK, PFE

    The healthcare sector has been one of the best sectors for dividend hunters -- most of the companies operating in the sector generate massive cash flow and payout a large chunk in dividends. Despite tight regulations and hefty investment in new technologies, these companies have been able to generate impressive growth figures.

    GlaxoSmithKline (NYSE: GSK), Pfizer (NYSE: PFE), and AstraZeneca (NYSE: AZN) are some of the star performers of the industry more »

  • Why Investors Should Consider These Fantastic English Stocks

    By Bob Ciura - July 23, 2013 | Tickers: GSK, UL, VOD

    Diversification is a subject most investors understand well. As the theory goes, it’s important to spread your bets so as to not become too heavily concentrated in one stock or industry. A critical piece of risk management is to not just try to maximize reward, but also minimize loss potential.

    While most investors are likely diversified across asset classes, within their equity portfolios, they may not be diversified geographically more »

  • Billionaire Ken Fisher’s Healthcare Picks for Q3

    By Meena Krishnamsetty - July 21, 2013 | Tickers: GSK, JNJ, NVO, PFE, SNY

    In mid July, Fisher Asset Management, the asset management firm run by billionaire and Forbes columnist Ken Fisher, filed its 13F for the second quarter of 2013 with the SEC, disclosing many of its long equity positions as of the end of June. Insider Monkey tracks these filings in our database, using them to help us develop investment strategies (for example, we have found that the most popular small cap more »

  • These Biotech Companies Are Facing Setbacks, but Investors Shouldn't Worry

    By Rupert Hargreaves - July 18, 2013 | Tickers: GSK, MRK, PFE

    Historically known as a defensive sector, biotech stocks have recently come under pressure as patent expirations, regulation, and litigation hit the industry.

    Most recently, executives working for the U.K.-based GlaxoSmithKline (NYSE: GSK) in China have been accused of, and confessed to, serious corruption and tax-related offences. Glaxo is not alone, as Chinese authorities are currently undertaking a sweeping analysis of foreign firms operating in the country in an more »

  • The U.S. Antidepressant Market: Old Fashioned Branding Might Save the Day

    By Amod Saul - July 18, 2013 | Tickers: AZN, AZN, LLY, FRX, GSK, PFE, TRGT

    Over 40% of Americans have used an antidepressant at least once during their lifetime and, at 270 million prescriptions per year, antidepressants are the most consumed class of therapeutics in the US. However, revenue does not match prescription numbers due to fierce generic competition in the class. While retail prices for commonly prescribed branded anti-depressants like Cymbalta can reach over $170 per month, a generic equivalent will cost less than more »

  • Could This Safe Play Help Eli Lilly?

    By Brandy Betz - July 11, 2013 | Tickers: BMY, LLY, GSK, NVO, SNY

    Note: This version has been amended to better reflect Victoza's dosage recommendations.

    At the American Diabetes Association meeting last month, Eli Lilly (NYSE: LLY) presented promising data for the GLP-1 agonist dulaglutide. GLP-1s are a well-established diabetes drug class dominated by Novo Nordisk (NYSE: NVO) and Bristol-Myers Squibb (NYSE: BMY).

    GLP-1 agonists are typically used as a second-line combo therapy for type 2 diabetes patients not responding to metformin more »

  • Page 1 of 9